Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2018
19 sept. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials...
Achaogen to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
18 sept. 2018 08h01 HE
|
Achaogen, Inc.
-- Company presentation scheduled for October 2, 2018 at 1:40 p.m. EDT -- SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company...
Achaogen Highlights Multiple Plazomicin Presentations at ESCMID/ASM 2018 Conference
04 sept. 2018 04h00 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR)...
Achaogen to Present at the Wedbush PacGrow Healthcare Conference
13 août 2018 16h01 HE
|
Achaogen, Inc.
-- Company presentation scheduled for August 14, 2018 at 8:00 a.m. EDT -- SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company...
Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06 août 2018 16h01 HE
|
Achaogen, Inc.
-- ZEMDRI (plazomicin), approved in the U.S. for the treatment of adults with complicated urinary tract infections -- -- Launch of ZEMDRI underway; reached more than three quarters of high priority...
CMS Grants New Technology Add-on Payment to ZEMDRI™ (plazomicin)
03 août 2018 08h00 HE
|
Achaogen, Inc.
--- Add-on Payment to Provide Additional Medicare Reimbursement up to 50% of the cost of ZEMDRI Prescribed to Medicare patients in Hospital Inpatient Setting --- SOUTH SAN FRANCISCO, Calif., Aug. ...
Achaogen Announces Strategic Update to Align Operations with Commercial and Clinical Development Priorities
26 juil. 2018 16h01 HE
|
Achaogen, Inc.
-- Restructuring to improve cost structure and focus corporate priorities to reduce overall capital needs -- -- Commercial and Medical Affairs teams unchanged by restructuring as the Company executes...
Achaogen to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 6, 2018
24 juil. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address...
Achaogen Launches ZEMDRI™ (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cUTI)
20 juil. 2018 08h00 HE
|
Achaogen, Inc.
-- ZEMDRI now available for ordering in the U.S. -- -- ZEMDRI demonstrated in vitro microbiological activity against pathogens designated by the CDC as urgent and serious public health threats,...
Achaogen to Host Investor Lunch Updating Investors on Commercial Strategy Post FDA Approval of Plazomicin on July 12th in New York City
10 juil. 2018 17h17 HE
|
Achaogen, Inc.
― Key opinion leaders Steven Burdette, M.D., (Professor of Medicine at Wright State University Boonshoft School of Medicine) and Joshua Rosenberg, M.D. (Chair of Critical Care at The Brooklyn Hospital...